Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 31, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on May 25, 2006:
- Previous Holdings: 17,425,862 Ordinary Share ADRs
- New Holdings: 17,411,245 Ordinary Share ADRs
- Transaction Price: Average price of $56.44
- Net Change: Decrease of 14,617 ADRs
Three directors (Dr J P Garnier, Dr T Yamada, and Dr M Slaoui) are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of the share transaction under Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the impact of the 14,617 ADR reduction on the total beneficial ownership of the three named directors.
- Confirm the average transaction price of $56.44 against market data for May 25, 2006.
- Review the full terms of the GlaxoSmithKline US Retirement Savings Plan to understand the discretionary nature of the fund movements.